Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα

[1]  A. Maurizi,et al.  The Osteoclast in Bone Metastasis: Player and Target , 2018, Cancers.

[2]  Yoshiya Tanaka,et al.  Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK‐RANKL system , 2018, Current opinion in pharmacology.

[3]  X. Liu,et al.  Hypoxia induces production of citrullinated proteins in human fibroblast‐like synoviocytes through regulating HIF1α , 2018, Scandinavian journal of immunology.

[4]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[5]  T. Nakashima,et al.  Recent advances in osteoclast biology , 2018, Histochemistry and Cell Biology.

[6]  J. Rho,et al.  Regulation of Osteoclast Differentiation by Cytokine Networks , 2018, Immune network.

[7]  Y. Soh,et al.  Macrolactin F inhibits RANKL‐mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP‐2/smad/Akt/Runx2 signaling pathway , 2017, European journal of pharmacology.

[8]  Soo Young Lee,et al.  Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation , 2017, Molecules and cells.

[9]  Jin Qi,et al.  Osteoblast Hypoxia-Inducible Factor-1α Pathway Activation Restrains Osteoclastogenesis via the Interleukin-33-MicroRNA-34a-Notch1 Pathway , 2017, Front. Immunol..

[10]  N. Lee,et al.  Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation , 2017, Molecules and cells.

[11]  Liren Li,et al.  Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis , 2017, Health and Quality of Life Outcomes.

[12]  H. Knowles,et al.  Hypoxia‐inducible factor 1‐alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl‐4‐hydroxylase 2 , 2017, The Journal of pathology.

[13]  Baojie Li,et al.  p38α MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner , 2017, Scientific Reports.

[14]  D. Peng,et al.  Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro. , 2017, Biochemical and biophysical research communications.

[15]  H. Yamanaka,et al.  RANK Expression and Osteoclastogenesis in Human Monocytes in Peripheral Blood from Rheumatoid Arthritis Patients , 2016, BioMed research international.

[16]  Mingli Yang,et al.  Eriodictyol Inhibits RANKL‐Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity , 2016, Journal of cellular physiology.

[17]  S. González-Chávez,et al.  Hypoxia and its implications in rheumatoid arthritis , 2016, Journal of Biomedical Science.

[18]  V. Nevzorova,et al.  Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease , 2016, Chinese medical journal.

[19]  D. Hao,et al.  Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption. , 2016, International immunopharmacology.

[20]  Shuhua Yang,et al.  Role of Epithelium Sodium Channel in Bone Formation , 2016, Chinese medical journal.

[21]  H. Knowles.  Hypoxic regulation of osteoclast differentiation and bone resorption activity , 2015, Hypoxia.

[22]  E. Rankin,et al.  Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin , 2015, Genes & development.

[23]  L. Deng,et al.  HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression , 2015, In Vitro Cellular & Developmental Biology - Animal.

[24]  Yongwon Choi,et al.  Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond , 2014, Front. Immunol..

[25]  M. Oyama,et al.  Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell–cell fusion , 2012, The Journal of cell biology.

[26]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[27]  M. Zaiss,et al.  Interleukin‐33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  M. Gillespie,et al.  Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. , 2011, Endocrinology.

[29]  A. Flanagan,et al.  Hypoxia stimulates osteoclast formation from human peripheral blood , 2010, Cell biochemistry and function.

[30]  Seng H. Cheng,et al.  Inhibition of osteoclastogenesis by prolyl hydroxylase inhibitor dimethyloxallyl glycine , 2010, Journal of Bone and Mineral Metabolism.

[31]  Zhangkun Li.  [Facing the challenge of low recognition and high disability in rheumatoid arthritis]. , 2009, Zhonghua yi xue za zhi.

[32]  H. Knowles,et al.  Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis , 2009, The Journal of pathology.

[33]  H. Lee,et al.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. , 2009, The Journal of clinical investigation.

[34]  B. Wouters,et al.  Hypoxia signalling through mTOR and the unfolded protein response in cancer , 2008, Nature Reviews Cancer.

[35]  J. Price,et al.  Hypoxia Induces Giant Osteoclast Formation and Extensive Bone Resorption in the Cat , 2006, Calcified Tissue International.

[36]  Y. Nogi,et al.  Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1* , 2004, Journal of Biological Chemistry.

[37]  T. Arnett,et al.  Hypoxia is a major stimulator of osteoclast formation and bone resorption , 2003, Journal of cellular physiology.

[38]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[39]  D. Mccarty,et al.  Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. , 1971, Arthritis and rheumatism.

[40]  K Lund-Olesen,et al.  Oxygen tension in synovial fluids. , 1970, Arthritis and rheumatism.

[41]  H. Takayanagi,et al.  Analysis of NFATc1-centered transcription factor regulatory networks in osteoclast formation. , 2014, Methods in molecular biology.

[42]  C. P. Winlove,et al.  Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. , 2008, The Journal of hand surgery.

[43]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.